Accordingly, inhibition of USP30 represents a potential actionable drug target for intervening the pathologies associated with PINK1/Parkin deficiency-induced mitophagy dysfunction, such as Parkinson’s disease and pulmonary fibrosis (Bingol and Sheng, 2016). This evidence concerns the gene USP30 and pulmonary fibrosis.